Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155648 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Giuseppe G Loscocco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Unive…. Hauptthemen laut MEDLINE: Thymus Neoplasms, Interferon alpha-2, Interferon-alpha, Polycythemia Vera. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Hepatoid thymic carcinoma (HTC) is an extremely rare variant of primary epithelial tumor of the thymus morphologically resembling hepatocellular carcinoma Herein, we report an additional case of HTC diagnosed in a 40-years-old man affected by polycythemia vera and treated with ropeginterferon alfa 2-b, for the first time deeply analyzing the molecular profile of this distinctive thymic malignancy. By immunohistochemistry, tumor cells were positive for cytokeratin 7-19, GLUT1, and Hep-Par-1, whereas AFP tested negative. Whole exome sequencing revealed loss of function mutations in TP53, STK11, PBRM1, SMAD3, FN1, NTRK1, and FANCD2, as well as gain of function mutations in MTOR, BCL11A and COL1A1, along with amplification of CCND3 and MDM2. This mutational landscape halfway between thymic carcinoma (TP53, PBRM1) and hepatoid variant carcinoma of other sites (STK11) suggests that, at some point during carcinogenesis, a switch occurred from an epithelial thymic phenotype to a hepatoid-like one.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
- Department of Medical Biotechnologies, University of Siena, Siena, Italy.
- Pathology Section, Department of Health Sciences, University of Florence, Florence, Italy.
- Department of Health Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
- Department of Clinical and Molecular Medicine, Sapienza University, Sant'Andrea Hospital, Rome, Italy.
- Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy; IFOM-ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Förderung
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Loscocco, G. G., Vannucchi, M., Santi, R., Amorosi, A., Scarpino, S., Siciliano, M. C., Guglielmelli, P., Tripodo, C., Di Napoli, A., & Vannucchi, A. M. (2024). Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155648
Vancouver
Loscocco GG, Vannucchi M, Santi R, Amorosi A, Scarpino S, Siciliano MC, et al. Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155648
BibTeX
@article{Loscocco2024,
author = {Loscocco, Giuseppe G and Vannucchi, Margherita and Santi, Raffaella and Amorosi, Andrea and Scarpino, Stefania and Siciliano, Maria Chiara and Guglielmelli, Paola and Tripodo, Claudio and Di Napoli, Arianna and Vannucchi, Alessandro M},
title = {Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155648}
}
EUVIMED